{"name":"Suzhou Sanegene Bio Inc.","slug":"suzhou-sanegene-bio-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SGB-3403","genericName":"SGB-3403","slug":"sgb-3403","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"SGB-3403","genericName":"SGB-3403","slug":"sgb-3403","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPaXptSUxvR3JFdzVrd2Q5cEthX19ZaEszLW5OXzNJRk1Od09RMVFPOEZSenZ1NWJ3b1ItUk5Id281Q1pyaE1PNnNndF9VT3ptSWZKUkNqNHRCS1JISk1Gb2o1NjAtTEN2RlhFU19hNU1YSHhPWEM2Ni1TcGRnTnZMZjh3bHAzTXVwMkx2eG93akEyQm5ubFVB?oc=5","date":"2026-02-03","type":"deal","source":"BioWorld News","summary":"Genentech licenses Sanegene’s RNAi asset in $1.7B deal - BioWorld News","headline":"Genentech licenses Sanegene’s RNAi asset in $1.7B deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOcjk4QUNKZTRBVlprVXBnZUR0cnU3RHNSYjFkRkZuamRWOW94WnBoNG5SUDhBR3NaRFpFUWZGQXR0RUlVZ2FuV2RsT0owYVYwRFd4bjY1eTBsbVdiVk4yVjBnODZqOUNON1FFQ3VZRTB2YnluWlhWcFNwUlFCQlBZUjRLbUNxOUk2WDNXSTBqNkhzVHN4MlE?oc=5","date":"2026-02-02","type":"deal","source":"Fierce Biotech","summary":"Roche's return to RNA continues with $1.7B deal for Sanegene program - Fierce Biotech","headline":"Roche's return to RNA continues with $1.7B deal for Sanegene program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQNnJsUkktYkd6ZWg3RjNGdDNGbmdqRmtMTWdYWDM3RkF3b1M4TTB2YlROT2NHemFvZ1JrTmczeUdRMVVmM2UwQ1ZJUUYxdXVIcjFqYjAtZG81TGRwbmQwLVVJODJ1dVhaWk8wYUlyMTV2T0hoSWhFXzNCaWYtcHZfQlZtZWhXZ1dFWnVjOTgxYmdGWFpwNEdfdzlZUWlYd2lLaXJNWnlXSVV0bFpESW5HUw?oc=5","date":"2025-12-09","type":"pipeline","source":"The Pharma Letter","summary":"Sanegene closes over $110 million series B to advance RNAi pipeline - The Pharma Letter","headline":"Sanegene closes over $110 million series B to advance RNAi pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNZy1DT2ZpVmRWejhfeWMwenZUOWR6WGVCNjVWZFZIRmZiY3J1elpSTGt4d0U0WHpNX3RYT2JoTnRSMmQzVktEUXF3aHh3U0pxZ2JqM3M0UGNvVFg2NDFjdXlOdzRNNXJLTjFPMkJtZDRXWG5MVng4MjlVdmdzT3hROGZUOVFoNzRwZWNUMGhLbl9MdnRYN09QdjlNT2F0TEFEeEE?oc=5","date":"2025-11-10","type":"deal","source":"BioWorld News","summary":"Lilly moves deeper into RNAi with $1.2B Sanegene obesity deal - BioWorld News","headline":"Lilly moves deeper into RNAi with $1.2B Sanegene obesity deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQcU1oeGhhNUtDNjg2eGVJLTc3dnk5ajUwM29CLWl1VkhWRkVqNUxHeUdSemM4emxVUlhaamVOMDJlU2l5bE04MDZSeTMwekZuUWNSajNOTHdFZ0FOQWJTemRkZHZRWDBVVzUyeWQtcDdqS0pxRHU0SEl4VlZjSlVmeVlDWmVHbE9TTVE4UmplM1FMNFUzVll3UnVydUJzZU5oei1LUXZJM2lwbXF2NEZUZmRKOWpvNmNFMkE?oc=5","date":"2025-11-10","type":"deal","source":"Reuters","summary":"Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease - Reuters","headline":"Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-31","type":"regulatory","source":"PR Newswire","summary":"Treatment Resistant Hypertension Market Set to Transform at a CAGR of 5% with Increasing Diagnosis and Treatment of Resistant Patients along with Approval and Development of Newer Therapies During the","headline":"Treatment Resistant Hypertension Market Set to Transform at a CAGR of 5% with Increasing Diagnosis and Treatment of Resi","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxOZkFxazBhb2trUC1Oa0d6S2Y3ZFlWb2pJWjBfRDJjZWdkVDNHRFlFV2U5bk16UHdRQ3FuWVl3RllacXJHQUVPRWRWYk5YZVZMRDRmZXYzNGlMZlFFSnAxaXpvSllTcHRPQ3NQRGdJZnB1b1FPSkV1WDNVT2cwUWlKU0cxVm5VbGkyQU5oUC1LNFRYYlhjeVRSY3NXRTMxei1RUVFqMFkwRlE4bURnRGJVZ2JUVmU1UWxkdUJRaXpIN0JQd2JRM0ZJUlFJT2FvV2pwelE?oc=5","date":"2025-05-20","type":"pipeline","source":"BioWorld News","summary":"Sanegene Bio’s SGB-3383 cleared to enter clinic in China for complement-mediated kidney diseases - BioWorld News","headline":"Sanegene Bio’s SGB-3383 cleared to enter clinic in China for complement-mediated kidney diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNU3YtTXJsOUV6QTRERmNhenRWakpjOWpYSHlTX29Sd2JuYlNlNEFRMXhfdU1CRVNiMi1kREZYZ2toUWFyczczeEtza2RnM3JWdmdRZEJQRVZ4Sk4zdGx2QTZXTjRnaTRLQ2pZd0cxMnlnVXFhY0UzY1BkVElXTV8yeC1Oam01bXVsRVRSR1RNNmNORTZSalRXUHUyQTlxTmhieGN5a2lfMGZ5b0pvREFnYmI0TlJ3UmN6cTVzVWh0SFhZVHFxcmJXek9YNmstZjRJSFlTdlVrSjdodw?oc=5","date":"2025-04-17","type":"pipeline","source":"PR Newswire","summary":"TRYVIO/JERAYGO Positioned to Redefine Treatment of Resistant Hypertension | DelveInsight - PR Newswire","headline":"TRYVIO/JERAYGO Positioned to Redefine Treatment of Resistant Hypertension | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQZzhCNkVRSzc3RHhSUmE5ajE0cjJ5ZTRWZmw2RTVQdlVfREtNYWsyMTIxd2dvRFZJbEJGT0hKZUJ1NVFYVHEwOVgzMDZLNkJTYmpFX01RRzV5WTNiM29aaGlpUmY2V2VLekl6bkpjYlhFT19GRzEwTHd0b2FOSlFscUUzY25INjlBdHdJSDRjQ09uc28tQWNZeGhLVndtU2N3VVdvdGRKRWp1OXpvazBTN0h1MzVheS1hVnNsMUVLY1dUcHNRVE02Y2M5c25zOWtpc0M1SUxKNVU3ZXdEa2JhTFhMQkFBTEQ1Q01KbkpIVnBCdXBmRlhJX1RB?oc=5","date":"2023-12-26","type":"deal","source":"PR Newswire","summary":"Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension - PR Newswire","headline":"Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}